for investors
veisund, at its real size
this page is what we would say in a first meeting, written down so you can check it before one. every number is dated. the small ones are printed at their real size, because the same follow-the-money standard the library applies to drug companies, regulators and medical associations applies to us.
are we raising? maybe. we would, if the partner and the trajectory are right. for now we are building relationships with funds whose thesis fits, so that the relationship exists before the round does. figures below were verified on 17 September 2026; the library figures come from the production database, not from memory.
what veisund is
two things that share one app and one website.
a peer-support community. people post what they are carrying under a handle they choose, real people who have been there reply, and the poster marks the thread resolved when they got what they needed. on the iphone app store since april 2020, on google play since august 2026, free, no ads. renamed from resolv social in september 2026.
an evidence library for psychiatric medication. what the trials actually found, what the regulator actually wrote, and who paid, for the drugs people are handed and the supplements they buy instead. every claim cites a trial, a regulator or a court record. every summary has a trust score computed from recorded facts about the paper, a written caveat where the source has a weakness, and a plain-language version written at an eighth-grade reading level. retracted papers are blocked from publication. the library is free to read on the web and inside the app.
the second thing is the asset. nobody else is writing the consumer-side evidence layer for psychiatric medication with the money trail beside the evidence, and the models people now ask about their prescriptions cite whoever has the sources.
what is true today
verified 17 September 2026.
the community is small. a median week over the last three months saw about five replies to posts. we briefly published a bigger number, audited it, found it was one unrepresentative week, and corrected it. what we can say is on what happens when you post, with its source.
why this, and why now
the person who is handed a prescription has the least information of anyone in the transaction. the library exists to fix that, and its own pages are the argument. the agency that approves the drug is paid mostly by the companies applying. three in four psychiatrists took an industry payment between 2015 and 2021, and the association that writes the diagnostic manual earns a third of its income selling it. the questionnaire that starts most prescriptions was paid for by pfizer. none of that is hidden. it is just not written where a person can read it, at a reading level they can read it at, on the day they need it.
the timing is the models. people now ask an assistant what sertraline does before they ask a doctor, and the assistants cite pages that carry primary sources, verbatim quotes and dates. a library built to that standard is the input those systems select for. we publish a machine-readable index of the whole library for exactly that reason.
how it makes money, and what it refuses
the app is free for the people who use it and will stay free. the revenue model is a flat listing fee in the expert directory: licensed therapists, coaches and peer specialists pay $29 a month to be findable, the first fifty founding listings get the first year free, and the fee buys a listing, not a ranking. no advertising, no subscriptions, no percentage of anyone's session revenue, no promoted placements, and no money from pharmaceutical companies, in the app, on the site or in the library. the policy, with what you can check and what you must take as stated, is on who funds veisund.
revenue today is immaterial and we say so. the directory is live and the founding cohort is open; the current operating focus is end-user reach and retention, not monetisation, because a directory without readers is a directory nobody pays for.
next: partnerships with prescribing organizations. the people reading a medication page are, by definition, people who need a prescriber who will read it with them. organizations that prescribe and manage psychiatric medication can partner with veisund to be the place those readers are referred, and pay a referral fee for it. the rules are fixed before the first dollar: the partnership is disclosed on the page where the referral happens, the fee never changes a word in the library, the reader is always told the organization is a partner, and the fee is structured to comply with federal and state anti-kickback and patient-brokering law, which for publicly insured patients rules out payment per patient. what is for sale is being findable by people who have already read the evidence, not the evidence.
the destination: a risk product. the money in mental health is not in apps. it is in the spend that organizations, health plans, employers and risk-bearing providers, carry for psychiatric medication, for avoidable inpatient stays that follow poorly managed medication regimens, and for open-ended therapy relationships that bill for years without measurable change. we believe the library, the community and measurement-based follow-up can be built into a product that takes financial risk on lowering that spend: medication regimens managed against the evidence rather than habit, fewer admissions from regimens nobody is watching, and an honest end to therapy that is not producing progress. the founder spent a decade building exactly this kind of product on the payer and provider side, including a $220 million capitated model, and that is the experience the destination draws on. it is a belief about where this goes, stated as one; nothing on this page counts it as revenue.
how it is built
one founder and a set of ai agents working under fixed editorial rules, with automated gates that do not care who wrote the sentence. the rules: every claim traced to a trial, a regulator or a court record; every quotation verbatim; funding recorded only where the document states it and marked unknown otherwise; both directions on every contested finding; no medical advice, ever. the gates: a daily check that re-tests every citation link in the library and fails the morning one breaks; a reading-level gate that rejects any plain-language field above ninth grade; a block on retracted papers; a daily health audit of the production library.
the practical consequence is the cost structure. the library grew from 251 summaries on 19 august 2026 to 353 on 17 September 2026, with pages, apps and quick reads shipping alongside, with no staff beyond the founder. the marginal cost of a sourced, verified page is close to zero. the cost that remains is distribution.
the stack, for the diligence file: a next.js site on vercel, native ios and android apps, a grails backend on heroku with postgres, and a content pipeline that reads pubmed and fda sources weekly and never publishes without a human-set rule passing. analytics carry no health data by design; the privacy policy is the one we actually run.
the founder
adam moen built veisund after his own crisis at twenty. professionally he spent more than a decade inside healthcare strategy and value-based care: chief of staff to a chief growth officer and director of strategy at optum, director of value-based care analytics for a $220 million capitated model at a large health system, and co-founder of a value-based primary care company acquired by blue cross blue shield of minnesota. he has led a nami minnesota youth group since 2013 and co-authored a peer-reviewed evaluation of a digital mental health intervention. he is based in excelsior, minnesota.
what a conversation is about now
three things. whether the thesis holds up when you read the pages. whether the numbers above, small as they are, move the way we say they will once the library is findable. and whether you want to know us before either of those is settled. if both come together with the right partner, that conversation becomes a round. materials, metrics and a walk through the library are available on request.
questions investors ask
- is veisund raising?
- maybe. we would raise if the partner and the trajectory are right: a fund whose thesis fits the library, and numbers that have started to move the way we say they will. until then we are building relationships, so the relationship exists before the round does. if you want to be on that list, email adam.
- what is the business model?
- three stages. today: a flat listing fee paid by licensed therapists, coaches and peer specialists who want to be findable in the expert directory, $29 a month, first year free for the first fifty. next: disclosed referral partnerships with organizations that prescribe and manage psychiatric medication, structured to comply with anti-kickback law and never touching the library. the destination: a risk-bearing product for health plans, employers and risk-bearing providers that lowers spend on psychiatric medication, on avoidable admissions from poorly managed regimens, and on open-ended therapy without progress. throughout: no ads, no user subscriptions, no promoted placements, no money from drug companies. the full policy is on the funding page.
- how big is it?
- small, and we print the real numbers. the play listing shows the 500+ download bucket, the app store shows a 5.0 from two ratings, and a median week over the last three months saw about five replies to posts. the library is the larger asset: 353 published research summaries and 777 web pages, every one sourced.
- who built it and who runs it?
- adam moen, the founder, with ai agents operating under fixed editorial rules and automated gates. there are no other employees. the legal entity is real empowerment solutions llc, minnesota.
- what would capital be for?
- reach and retention: getting the library in front of the people who are handed a prescription this week, and making the app the place they come back to. the cost of producing sourced content is already near zero; the cost of being found is not.
the apps: app store · google play. the library: everything we publish. the method: how we score evidence.